DURHAM, N.C.–(BUSINESS WIRE)– The U.S. Food and Drug Administration (FDA) approved Vivjoa (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of…Original Article
FDA Approves Vivjoa (oteseconazole) for the Treatment of Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)
